- Home
- CUE vs AIRG Comparison
CUE vs AIRG Comparison
Compare CUE & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | AIRG |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 47.4M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CUE | AIRG |
|---|---|---|
| Price | $0.49 | $4.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $6.33 |
| AVG Volume (30 Days) | ★ 249.2K | 54.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,100,000.00 | ★ $54,737,000.00 |
| Revenue This Year | $36.58 | N/A |
| Revenue Next Year | $32.10 | $16.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $3.00 |
| 52 Week High | $1.75 | $8.53 |
Technical Indicators
Market Signals| Indicator | CUE | AIRG |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 50.60 |
| Support Level | $0.47 | $3.90 |
| Resistance Level | $0.51 | $4.08 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 10.78 | 33.76 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.